Sarepta Therapeutics(US:SRPT)2025-02-27 04:49Financial Performance - Total product revenue for FY 2024 reached $1788 million, a 56% increase compared to $1145 million in FY 2023[39] - Q4 2024 total product revenue was $638 million, a 75% increase compared to $365 million in Q4 2023[38] - Sarepta achieved GAAP operating income of $218 million in FY 2024, compared to a loss of $268 million in FY 2023[39] - Non-GAAP operating income for FY 2024 was $438 million, compared to a loss of $42 million in FY 2023[39] - The company secured a $600 million revolving credit facility[13, 37] - Sarepta announced a $500 million share repurchase program[13] Product Performance - ELEVIDYS launch contributed to strong revenue growth, with Q4 revenue exceeding guidance by over $60 million and growing 112% over the previous quarter[19] - PMO products remained a steady contributor to net product revenue[13] Future Outlook - Sarepta anticipates total product revenue between $2900 million and $3100 million for FY 2025, representing approximately 68% growth at the midpoint[40] - Combined Non-GAAP R&D and SG&A expenses are projected to be between $1200 million and $1300 million for FY 2025[40]